View Older Stories View More Recent Stories

Jun 11, 2023 08:30AM Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Jun 5, 2023 04:02PM Intellia Therapeutics (NTLA) Announces Resignation of Jean-François Formela from Board
Jun 5, 2023 04:01PM Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
May 31, 2023 07:41AM Intellia Therapeutics (NTLA) to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema
May 31, 2023 07:30AM Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
May 4, 2023 07:30AM Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 1, 2023 07:30AM Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
Apr 27, 2023 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
Apr 17, 2023 04:01PM Intellia Therapeutics (NTLA) Appoints Bill Chase to its Board
Apr 17, 2023 04:01PM Intellia Therapeutics Names Bill Chase to its Board of Directors
Mar 21, 2023 07:32AM Intellia Therapeutics (NTLA) Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NTLA-2002
Mar 21, 2023 07:30AM Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
Mar 2, 2023 07:01AM Intellia Therapeutics (NTLA) Announces FDA Clearance of IND Application for NTLA-2002
Mar 2, 2023 07:00AM Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (H
Feb 23, 2023 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Feb 16, 2023 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
Jan 11, 2023 07:30AM Intellia Therapeutics (NTLA) Awarded Innovation Passport in the UK for NTLA-2002
Jan 11, 2023 07:30AM Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Jan 5, 2023 07:30AM Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Nov 30, 2022 04:37PM Intellia Therapeutics (NTLA) to Offer $250M in Common Stock
Nov 30, 2022 04:36PM Intellia Therapeutics Announces Proposed Public Offering of Common Stock
Nov 12, 2022 04:30PM Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022
Nov 5, 2022 04:00PM Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the
Nov 3, 2022 07:30AM Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Oct 31, 2022 07:30AM Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting
Oct 27, 2022 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates
Sep 26, 2022 07:30AM Intellia Therapeutics to Present at October Healthcare Investor Conferences
Sep 16, 2022 07:16AM Regeneron (REGN) and Intellia (NTLA) Report Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001
Sep 16, 2022 07:15AM Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Sep 16, 2022 07:15AM Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Sep 16, 2022 07:02AM Intellia Therapeutics (NTLA) Reports Positive Interim Data for NTLA-2002
Sep 16, 2022 07:00AM Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
Sep 14, 2022 01:05AM Jeito Capital co-leads €75 million Series B financing in SparingVision
Sep 14, 2022 01:00AM SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
Sep 8, 2022 04:01PM Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022
Sep 1, 2022 04:01PM Intellia Therapeutics (NTLA) Granted FDA Orphan Drug Designation for NTLA-2002
Sep 1, 2022 04:01PM Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema
Aug 23, 2022 09:59AM Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium
Aug 4, 2022 07:30AM Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Jul 27, 2022 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
Jun 24, 2022 07:31AM Intellia Therapeutics (NTLA) and Regeneron (REGN) Report Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001
Jun 24, 2022 07:31AM Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Rema
Jun 24, 2022 07:30AM Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Rema
Jun 8, 2022 07:30AM Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 20
May 5, 2022 07:30AM Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 2, 2022 04:01PM Intellia Therapeutics (NTLA) Appoints Muna Bhanji to its Board
May 2, 2022 04:01PM Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
May 2, 2022 07:31AM Intellia Therapeutics (NTLA) Reports Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform
May 2, 2022 07:30AM Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
Apr 28, 2022 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
View More Recent Stories View Older Stories